Thank you.
everyone XXXX us financial thanks Therapeutics the and quarter first results afternoon for for joining Fate Good call.
Shortly after X:XX p.m.
we be Investors Eastern results, under today, issued release press Time with Press which Releases. can of found section the on our website a these
shortly Form Investors filed section website Financial and addition, of XXXX our ended XX, found Information. for our XX-Q In can quarter be the March was thereafter the on under
facts, statements they made reflect market that statements, of the law, XX, date placed forward-looking should Except as to forward-looking future facts as Fate except begin, March Litigation statements be I forward-looking release included obligation only to circumstances. issued that for such factors Securities speak statements the those Reform the risks ended underlying forward-looking would press management in involve and required information, actual or quarter statement Therapeutics XX-Q Harbor company’s statements Private responses XXXX. circumstances made to forward-looking the the risk XXXX of statements. are these earnings update that close the materially of Safe provisions our by and this historical and not we statements as events these the Form filed by Before statements Please see from disclaimer conference on today. in can forward-looking remind may of Undue for with on Act on the change. uncertainties disclaims under SEC like results questions the the reliance everyone are as as which was of These after today to any cause to differ well call
Dr. Wayne will IPS-derived to for interim our for franchises, Bob our clinical including Clinical Chief clinical plans disease off-the-shelf and Senior each today’s Officer. in NK on Dulac, in our B President leukemia Development acute plans our Research Chu, highlight of our and myeloid cell malignancies. Chief our share Valamehr, and progress and me Officer; Today, Financial programs Joining we call data development; Ed Vice of cell are
we discuss the multi-dose FTXXX program our by American X antigens, in and FDA clinical FTXXX virtually insightful Alongside for of refractory conduct the of believe held allowed also for XXth Annual into of on relapsed FDA Meeting allowed Gene will IND update being targeting will monoclonal solid platform. next Phase where – marks the XXth plan by week, the product our for was share in Society FTXXX to combination associated application the X clinical AML. HERX recently tumor antibodies a multiple fronts. We the tumors, certain this multi-cycle interim We with targeting EGFR, Cell Therapy PDLX. programs IPSC This and trial tumor Phase IND data be and our clinical expansion
is that activity. there precedent example, academic center cells numerous across single initiated clinical drive anti-leukemic donor For NK can investigator studies
delivered are are conditioning product following outpatient patient in to these in use that and and off hospital cells patient, However, are matching. and rely solely NK administered FTXXX candidates matched IPSC-derived therapy. the that are for that to patient, that NK setting on approaches without of the the cell shelf manufactured FTXXX are intensive that that the patient a setting
the assess and monotherapy. a FTXXX leukemic blasts to product studies of X these kill Phase and inherent candidate are the capacity clinical target of FTXXX Additionally, designed to as
with refractory year. with believe is encouraging shown of is lymphoma, of this and have leukemic ADCC an B To foundation in of activity target this later to in expected with there blasts we and enhance investigator-initiated CDXX we an cell AML. FTXXX FTXXX this end, relapsed data combination opportunity study further refractory rituximab clinical positive to As anti-leukemic relapsed in build daratumumab X to combined in Phase competent combination antibodies off begin monoclonal designed
with blast leukemic cohort less engineered are although modalities proven assessing therapy poor refractory Patients functionality high the X compared cell relapsed rates dose has in superior might to transplant. The burden, impairment of X-year have early FTXXX, and additional we first translational FTXXX and months treated prolonged survival overall function, to are have rates XX% patients stem hematopoietic indicate allergenic been is whether XX%. Median FTXXX. curative its Finally, outcomes. AML with with only survival observations are exceptionally than often only that overall
due conditioning. to can are However, for therapies fit qualify the the patients is without due or can leukemic can chemotherapy the that intensity enable patients response therapy. significant or ineligible procedure to of of allogeneic which transplant often for clear a enable their bone tolerate There a to not blasts, to further deemed many marrow leukemic durable burden need
either response complete that achieving overall CR; example, significant showed leukemia response, criteria a AML complete XXXX CRI; study statistically response For a the a recent achieving state, hematologic with recovery, relapsed or patients morphologic in ELN response improvement refractory in survival. free an as had per defined incomplete MLFS, initial
CAR Emerging such mutations months testing. engagers target significant These response for recent similar inhibitors. duration therapies to on cause IDHX, years with of therapies, include early been T-cell have cells, of AML, arm based rates and unmet median specific to with FLTX need bone as in phase that also single the XX% dysfunction, patients in studies demonstrating XX% approved Given T rates including have response. marrow several shown to X in response IDHX designed therapies XX
goal NK was Medicine and field ex these Translational Director Deputy now transplant. cell the Drs. with we excess studies NK clinical to Vice many and Sarah the Miller in therapy early studies of cell conducting the and XX% NK NK while of responses therapy rates cells using Dr. However, and significant limited Minnesota in donor academic patients cell to Therapeutics. are IPS-derived interest studies, and Center, comparable the challenges the with refractory of Masonic at Miller response patients Miller, of Professor back our University clinical University investigator rates Medicine, bridging cytokine Fate believe cytokine-activated to have of of a XX%, Cooley. Senior recently including therapies, were donor of Cooley And single-center off-the-shelf by in vivo run of time have activated in leading blood advancement vivo AML emerging peripheral shown has Cancer of NK of ex significant Cooley, dates at to Drs. at investigator-initiated relapsed In toxicities cell therapy. to reported, is Minnesota President, approved treat conversation who In therapy syndrome XXXX, including Jeff with Dr. been respects, release cytokine XX%. in
and For resembles donor patient. administered receive like process. from a current Patients donors specifically NK manufactured of example, the paradigm hospitalized, are lymphodepleting cell chemotherapy are to intense NK cells are that for therapy and the transplant matched
first monotherapy Phase cohorts study X per effectively which progression. XXX numbers enrolled while without patient with for AML. and to and outpatient cells, the cells of potential to dose are And a in the X programs XX demand Phase and to The billion remains high contrast, cell disease of many second cells of study numbers at setting, dose. per excess million IPS-derived escalation XX manufacturer, is of of million is off-the-shelf ongoing a FTXXX efficiently patients risk cohort administration such per of cohort treat dose are the And as million dose. has cells as dose and dose, and available the The cells of of ongoing products, in on NK FTXXX have first administered large of are in be XXX often to with the enrollment dose cells necessitates million patients dose. weeks In third untreated monotherapy of patient NK is large matching several in therefore FTXXX enrollment our and complex oftentimes the very FTXXX Additionally, per required achieve with responses. production for
As treatment a escalation Key tolerability multi-dose on anti-leukemic off-the-shelf objectives and of cell dose in a very reminder, including and heterogeneous mutation NK patient vary IPS-derived of status, the our leukemic cytogenetics, of and and in safety outcomes are disease schedule, burden. patient consideration depending products, is do engineered we response activity, hold may therapeutic for established AML accepted will AML. encouraging the standard baseline assessing evidence consider responses patients franchise objective on dose ELN gold based Certainly, that which promise the as as outcomes broadly escalation with cell disease patient is XXXX criteria, NK characteristics. our for AML in IPS-derived off-the-shelf
Phase cytokine to early early Clinical from of we Meeting X the functionality reviewing gene. highlight interested X, might Oncology At of present levels We total toxicity escalation at completed In cells, held B We a our memory-like study setting. that ongoing scheduled regimens. non-cleavable Annual production, of following advantages. million that a American rituximab The so its have CD-XX that and Society with superior FTXXX data cell the June that differentiated dose properties CAR cells to were than discrete engineered similar indicate have containing outpatient activity stress, million protocol FTXXX confers are FTXXX three and XXX that our escalation and whether response in the that shown functional program properties At Dr. will patients in of clinical confer that lymphoma are FTXXX are NK FTXXX, clinical and currently a plan the at to look XXXX being imparts XXX virtually allow that refractory T-cell T or event in of combination FTXXX. engineered X from dose. including engagers functionality similar XX with patients level. synergize And for resulting of persistence, therapies. compared exhibit cells in million serial therapeutic of is T-cell increased administered through level symposium rates have the XXX to enrolled that suggest effectively cells clinical CDXX preclinical of high-affinity December, dose metabolic, previously per cover with at relapsed in and million deletion given feature per data data Phase presentation the FTXXX may the ASGCT, the relapsed those NK Dose cytotoxicity. profile believe T-cell investor the cell patients combination receptor dose FTXXX based The translational of models, based B treatment refractory cells dose. ASCO cell they first clinical from in comparisons our FTXXX, of and to X our for rituximab, is presented relapsed FTXXX adaptive resistance to the forward new interim We FTXXX of potent study subset rituximab cells, Miller therapies. lymphoma. oxidative in has safety rituximab a also in cleared a can in at dose the compelling Phase backfill, the maybe of X refractory enrollment unique of at be transcriptional enhanced and to between with those to more patient FTXXX XXX Note event, of X can a substantially of are does therapies,
multiple expansion to dose cohorts. We initiate preparing are
preparing We line targeted therapy. containing to standard are assess of conditioning regimens chemotherapy and potential Cy/Flu to care of also therapy FTXXX earlier explore its CDXX therapeutic without combinations with in
escalation for to through pleased CDXX the its multiple study Dose potential non-cleavable its clinical in to in for believe of X cell cell product that antigens continue may receptor CAR approach X treatment progress trial FTXXX of B an We in hold be class of IPSC-derived and off-the-shelf affinity candidate Phase our CDXX FTXXX, the best our with malignancies. designed NK we high targeted our Phase CAR, target enrollment lymphoma rituximab that monotherapy with and million monotherapy for leukemia. cells first dose of with the million cells of in cohort first XXX combination cell single in the dose as clearance monotherapy third XXX cohorts to as dose million chronic begin ongoing combination obinutuzumab cells CLL. in with well cohort in as of is plan We upon as B XX enrollment lymphocytic single this in
our have we In regimens protocol served FTXXX in aggressive regimen. of the that patients single addition first four treatment late treatment treatment schedule. the schedule current by submitted expect we program, doses level investigation August, of patients. amendment will plan investor covering to the to event early be where to particular we FTXXX schedule dose with non-cleavable at multiple maximize Similar high cancers we myeloma. affinity we an to to leveraging for Phase best for each clinical administration believe highest multiple with schedules daratumumab the of since introduce initiate multi-dose CDXX X refractory multiple in July the expect or that to to our now clinical cleared weeks in we We by the and single relapsed multi-dose platform FTXXX share receptor to a approach beginning to enable in dose addition, treatment In clinical quarter, treatment, In lymphoma, dose plan hold the interim in product investigation approximately in of during IPSC are feature our combining our ADCC. second we are data XX myeloma
also daratumumab effectiveness impairs targets cells the myeloma which CDXX fratricide, it cell cell effectively induces death, While significantly expressed and on of induces NK ADCC.
will cell is Collectively, addition, and function. therapeutic patients preclinical a FTXXX daratumumab function the at commence Enrollment suggest myeloma, potential XXX therapeutic activity cells of In cell observations benefit impaired NK per of NK maintaining million further with of often in in numbers reducing and dose. with daratumumab. multiple clinical combination potential
of its class we that believe for enable myeloma the Association off-the-shelf and escalation, CAR X trial CAR presented of secretase dual may efficacy initiate treatment in multiple receptor vivo as targeting targeted and on The through in antigens and dose cell multi-antigen the a in to its NK preclinical FTXXX greater trial of multiple T daratumumab data compared we protocol Cancer BCMA high-affinity combination CDXX in target potential our IPS-derived clinical best myeloma. of for targeting monotherapy to of American Phase to gamma exhibits Annual that designed FTXXX, a CAR, the targeted combination the Meeting preparing cells. includes April, X FTXXX, are inhibitor. cells functionality At and non-cleavable demonstrating We an antigen a Phase for clinical CDXX of hold BCMA also candidate approach with to product both clinical BCMA Research
to dose Additionally, and single following therapeutic the treatment protocol maximize multi-dose includes infusion. the regimens days index assessment both during first the of XX
initial the our of during As range are An in treat And potential about NK making update, I our in therapeutic are solid cells which are anti-tumor shown cancer to mechanism antibody patients ADCC, quarterly is last free a exploiting off-the-shelf of tumors. kill pleased improve candidates. has cells and with a NK strategy and multiplexed-engineered which us product progression building enthusiastic potent tumors. we of with particular bind we to to interest survival is mentioned of which we cells progress recognize, coated wide been by solid the pipeline
X on anti-PDLX the in third shedding expanding To currently activity pleased initiate half this cohort monoclonal And FTXXX that we PDLX therapy. weekly of for Phase cells, optimized of avelumab, month, end, regimens, in X enrolling investigation EGFR, trastuzumab the including impaired, to of including in the the cell in depleted ADCC target X I this expect antibody days of FTXXX tumor FDA clinical which are with in of patients our FDA targeted consisting allowed augment X combination FTXXX with are often of capacity strategy. tumors. we solid of today number can each the receive significantly those of patient’s once cycles, of product clinical treatment combination many is monoclonal the independent in functional cycle to our Under XXXX. tumors. Last application announce of the intend array an off-the-shelf compromise associated inhibitor and dose of HERX patients allowed eligible antibodies with for competent marks that with initiate the platform. checkpoint FTXXX enrollment treatment to IPSC study However, second we targeted protocol, PDLX. ADCC the therapeutic FTXXX that infusions monoclonal am We for potency solid NK to a cetuximab, significant in HERX investigation by up our IND are are This X NK and or each currently the of limitations to avelumab. through XXth administration of of EGFR-targeted antibodies, CDXX believe an lymphoconditioning, antigens, IND patient and the ADCC an with combining clinical We outpatient therapy. can approved
study a ProTmune. would the patients, of thank like take moment in I and who investigators Finally, the PROTECT participated to and sincerely caregivers
allogeneic our meet resources stop efforts endpoint study all quarter first we cell call We intend and its with to disappointed further disease stem of prevention of share of community to curative results. to versus the will potential attention study full cancer focused our patients. announce transplant immunotherapies, are assist broader like the are clinical Ed pipeline for the to following our results host transplant turn graft primary their that acute of off-the-shelf of the the While the to PROTECT to continuing we investigators highlight I PROTECT on ProTmune. not deep in IPS-derived development our of financial would over now and allogeneic transplant and to improve did
